Wegovy UK
Wegovy UK: The Complete Plain English Guide
The plain English UK guide to Wegovy. How semaglutide works, the 2.4mg and 7.2mg injections, side effects, NHS access, private treatment and what UK patients need to know before starting.
What is Wegovy?
Wegovy is the UK brand name for semaglutide when it is prescribed for weight management and, in a separate indication, to reduce major cardiovascular events in certain adults with established cardiovascular disease. Semaglutide is also used in Ozempic for type 2 diabetes and in the newer Wegovy tablet, but these products have different doses, formulations and licensed uses.
For weight management, Wegovy is authorised alongside a reduced-calorie diet and increased physical activity for adults with obesity, or adults who are overweight and have at least one weight-related health problem. The standard injection is taken once weekly and is gradually increased from 0.25mg to the usual 2.4mg maintenance dose.
Since January 2026, adults with obesity only, meaning a BMI of at least 30, may be prescribed up to 7.2mg weekly if clinically appropriate after reaching and tolerating 2.4mg for at least four weeks. A single-dose 7.2mg pen was authorised by the MHRA in April 2026. The higher dose does not apply to people with BMI below 30 using Wegovy for weight management or to the cardiovascular-risk-reduction indication.
How does semaglutide work?
Semaglutide is a GLP-1 receptor agonist. GLP-1 is one of the body’s signalling hormones involved in appetite, food intake and blood-glucose regulation. Semaglutide also delays gastric emptying, particularly around treatment initiation and dose escalation.
For many people the practical effect is less hunger, earlier fullness and lower food intake. People often describe this as reduced ‘food noise’, although the strength of the effect varies between individuals.
Mounjaro contains tirzepatide and activates both GIP and GLP-1 receptors. In the direct SURMOUNT-5 obesity trial, maximum tolerated tirzepatide produced 20.2 percent average weight loss at 72 weeks compared with 13.7 percent for maximum tolerated semaglutide 1.7mg or 2.4mg. The newer 7.2mg Wegovy dose was not tested in SURMOUNT-5, so it is not accurate to say that trial shows the higher-dose gap has narrowed.
Wegovy vs Mounjaro vs Ozempic – the honest comparison
Ozempic and Wegovy both contain semaglutide, but Ozempic is the UK product authorised for type 2 diabetes, while Wegovy has weight-management and cardiovascular-risk-reduction indications. Using Ozempic specifically for weight loss is outside its UK licensed indication.
In STEP 1, Wegovy 2.4mg produced 14.9 percent average weight loss at 68 weeks under the trial’s treatment-policy estimand. STEP UP then tested 7.2mg in adults with obesity without diabetes. At 72 weeks, the higher dose produced greater average weight loss than 2.4mg, with the published trial reporting results under both treatment-policy and efficacy estimands. The widely quoted 20.7 percent figure is the efficacy-estimand result, so it should not be compared as though it were measured identically to every Mounjaro trial result.
The cleanest direct comparison remains SURMOUNT-5: tirzepatide 10mg or 15mg produced 20.2 percent average weight loss versus 13.7 percent with semaglutide 1.7mg or 2.4mg at 72 weeks. There is not yet a head-to-head trial of tirzepatide against Wegovy 7.2mg.
That means there is no sound basis for declaring Mounjaro and 7.2mg Wegovy ‘broadly comparable’ from separate trials alone. Treatment choice also depends on licensed indication, eligibility, tolerability, contraindications, availability, cost and prescriber assessment. For the wider evidence, see our weight loss jabs and pills compared guide.
What did the STEP trials actually show?
The STEP programme established semaglutide’s effectiveness for weight management. STEP 1 enrolled 1,961 adults with obesity, or overweight plus at least one weight-related condition, without diabetes. At 68 weeks, semaglutide 2.4mg produced 14.9 percent average weight loss compared with 2.4 percent with placebo under the treatment-policy estimand.
STEP UP later tested semaglutide 7.2mg against 2.4mg and placebo in adults with obesity without diabetes. The study ran for 72 weeks and supported the UK authorisation of the higher dose. The 20.7 percent figure commonly quoted for 7.2mg is the efficacy-estimand result, which estimates the effect if treatment was taken as intended; the treatment-policy analysis was lower. This distinction matters when comparing results across different trials.
The MHRA first authorised a maximum 7.2mg weekly regimen in January 2026 for adults with obesity only. Initially this required three consecutive 2.4mg injections on the same day. In April 2026, the MHRA authorised a single-dose 7.2mg pen, so the current UK product can deliver the full higher dose in one injection.
Both STEP 1 and STEP UP combined medication with lifestyle intervention. Their group averages are useful evidence, but they are not a prediction of how much any individual will lose.
Side effects – the full honest picture
The most common Wegovy side effects are gastrointestinal. Nausea, diarrhoea, vomiting, constipation and abdominal pain are all listed in the UK product information, and symptoms are particularly common while the dose is being increased. Vomiting and diarrhoea can sometimes cause dehydration, which may require medical attention.
There is no evidence-based rule that Wegovy should be injected in the evening. It can be taken at any time of day. Smaller meals and avoiding foods that clearly worsen symptoms may help some people, but persistent or severe symptoms should be discussed with the prescriber rather than simply pushed through.
Acute pancreatitis is an uncommon but important risk. In January 2026, the MHRA strengthened warnings after reports that included rare necrotising and fatal pancreatitis. Severe, persistent abdominal pain that may radiate to the back, with or without nausea or vomiting, needs urgent medical assessment. If pancreatitis is suspected, semaglutide should be stopped; if confirmed, it should not be restarted.
The previous version of this guide repeated a US-style warning about medullary thyroid cancer and MEN2. That is not listed as a UK Wegovy contraindication in the current SmPC; the UK contraindication is hypersensitivity to semaglutide or an excipient. Individual medical history still matters and should be reviewed by the prescriber.
Another 2026 safety update concerns the eye condition NAION, which has been very rarely reported with semaglutide. Sudden loss or rapid worsening of vision needs urgent medical attention.
Wegovy itself does not automatically have to be reported to the DVLA. You must not drive if side effects or a medical condition make you unsafe to drive, and separate DVLA rules apply to notifiable conditions.
How to get Wegovy on the NHS
There are now two distinct NICE routes relevant to Wegovy in England, and they should not be confused.
For weight management, NICE TA875 recommends semaglutide 2.4mg for adults with at least one weight-related comorbidity and a BMI of at least 35, with lower thresholds in some circumstances, within a specialist weight-management service. Under TA875, treatment for weight management is limited to a maximum of two years.
Separately, NICE TA1152 was published in May 2026 for cardiovascular risk reduction. It recommends semaglutide up to 2.4mg weekly for adults with established cardiovascular disease, specifically previous myocardial infarction, stroke or symptomatic peripheral arterial disease, and a BMI of at least 27. This is a different indication from weight management and the guidance does not restrict prescribing to a Tier 3 weight-management service.
The SELECT trial behind that cardiovascular indication found a 20 percent relative reduction in the composite risk of cardiovascular death, non-fatal heart attack or non-fatal stroke compared with placebo. NICE estimated that more than a million people could potentially meet the broad criteria, but individual prescribing still depends on clinical suitability and local implementation.
In England, normal NHS prescription-charge rules apply unless you are exempt or covered by a valid prepayment certificate. Scotland, Wales and Northern Ireland have different prescription-charge arrangements.
How to get Wegovy privately
Private Wegovy is available through regulated UK pharmacies and prescribing services. Because semaglutide is prescription-only, a legitimate provider should carry out an appropriate clinical assessment before supplying it and provide a route for follow-up and safety advice.
For pharmacies in Great Britain, check the dispensing pharmacy on the General Pharmaceutical Council register. If a separate online doctor or healthcare service provides the clinical consultation in England, you can also check whether that service appears on the Care Quality Commission register where applicable. Northern Ireland uses a different pharmacy regulator.
Be cautious of sellers offering prescription weight-loss medicines without a proper assessment, through social media, or from an unregulated website. The MHRA continues to warn that illegal and falsified weight-loss medicines are being sold online in the UK.
Our UK Clinic Reviews cover individual providers. Inclusion on this site is not a substitute for checking the relevant regulator or for an individual medical assessment.
What does Wegovy cost in the UK?
In England, normal NHS prescription-charge rules apply unless you are exempt or use a valid prepayment certificate. Prescriptions are free in Scotland, Wales and Northern Ireland.
Private Wegovy prices vary by dose, provider and any consultation, delivery or membership charges. Because prices change frequently, a fixed £130 to £300 range can become misleading quickly. Use our Wegovy price comparison for the latest prices we have checked across UK providers.
The 7.2mg dose is only authorised for adults with obesity and only after the standard 2.4mg dose has been reached and tolerated. It may be priced differently from standard-dose Wegovy, so check exactly which dose and product the quoted price covers.
Very low prices are not proof of a bargain. Check the pharmacy, prescription process and product source as well as the headline cost.
What happens when you stop Wegovy?
Weight regain after stopping semaglutide is common, although the amount varies between individuals.
In the STEP 1 extension, a subset of participants was followed for one year after semaglutide 2.4mg and the trial lifestyle intervention were stopped. During treatment they had lost an average 17.3 percent of body weight. Over the following year they regained 11.6 percentage points, roughly two-thirds of the weight they had lost, leaving an average net loss of 5.6 percent from their original weight.
That extension was exploratory and involved 327 participants, so it should not be read as a guarantee that every person will regain two-thirds. It does show clearly that the biological effects of treatment do not simply persist unchanged after semaglutide is withdrawn.
For people using Wegovy under the cardiovascular indication, the proven SELECT benefit was demonstrated while participants were receiving treatment; it should not be assumed to continue after stopping.
Maintaining weight loss long term
Wegovy is licensed to be used alongside a reduced-calorie diet and increased physical activity, and weight-management support remains important whether treatment is continued or stopped.
The evidence does not support promising that lifestyle changes will reliably prevent regain after semaglutide withdrawal. The STEP 1 extension showed substantial average regain even after participants had previously received lifestyle intervention alongside treatment.
There is also no general UK product-information or NICE requirement to taper Wegovy gradually before stopping. The previous version of this page overstated that point. If treatment is being stopped because of side effects, pregnancy planning, another medical issue or a change in treatment plan, the timing should be discussed with the prescriber rather than following an unsupervised taper.
Swipe sideways to see the full table →
|
Treatment |
Average Weight Loss |
Receptors Targeted |
UK Status |
Live Pricing |
|---|---|---|---|---|
|
Retatrutide |
28.3% |
3 (GLP-1 GIP Glucagon) |
Not approved |
Coming soon |
|
Mounjaro |
20.2% in SURMOUNT-5 |
2 (GLP-1 GIP) |
Approved |
|
|
Wegovy (injection) |
14.9% (2.4mg); up to 20.7% efficacy estimate (7.2mg) |
1 (GLP-1) |
Approved |
|
|
Ozempic |
Not licensed for weight loss |
1 (GLP-1) |
Diabetes only |
Coming soon |
|
CagriSema |
20.4% in REDEFINE 1 |
2 (GLP-1 Amylin) |
Not approved for weight management |
Coming soon |
|
Wegovy Pill |
13.6% in OASIS 4 |
1 (GLP-1) |
Approved in UK |
Coming soon |
Frequently Asked Questions
How much weight will I lose on Wegovy?
STEP 1 reported 14.9 percent average weight loss at 68 weeks with semaglutide 2.4mg under the treatment-policy estimand. STEP UP found greater weight loss with 7.2mg; the widely quoted 20.7 percent figure is the efficacy-estimand result. Individual results vary and these trial averages are not a prediction for one person.
Is Wegovy the same as Ozempic?
They contain the same active ingredient, semaglutide, but they are different products with different UK indications and doses. Ozempic is authorised for type 2 diabetes. Wegovy is authorised for weight management and, in eligible adults, cardiovascular risk reduction. Using Ozempic specifically for weight loss is outside its UK licensed indication.
Can I get Wegovy on the NHS?
Yes, but there are different NHS routes. NICE TA875 recommends semaglutide for weight management in a restricted population through specialist weight-management services and limits treatment to two years. NICE TA1152, published in May 2026, separately recommends semaglutide up to 2.4mg for reducing major cardiovascular events in adults with established cardiovascular disease and a BMI of at least 27. Local access and clinical suitability still matter.
What is the new Wegovy 7.2mg dose?
The MHRA authorised a maximum 7.2mg weekly Wegovy dose in January 2026 for adults with obesity only, after they have reached and tolerated 2.4mg for at least four weeks. A single-dose 7.2mg pen was authorised in April 2026. The higher dose does not apply to people with BMI below 30 using Wegovy for weight management or to the cardiovascular-risk-reduction indication.
What is the difference between the Wegovy injection and the Wegovy pill?
Both contain semaglutide. The injection is taken once weekly, while the Wegovy tablet authorised by the MHRA in June 2026 is taken once daily, starting at 1.5mg and increasing to 25mg. The tablet must be taken according to specific fasting instructions because food and timing affect absorption. Our Wegovy Pill UK Guide covers it in full.
What is the difference between Wegovy and Mounjaro?
Wegovy contains semaglutide and targets the GLP-1 receptor. Mounjaro contains tirzepatide and targets GIP and GLP-1 receptors. In the direct SURMOUNT-5 trial, tirzepatide produced 20.2 percent average weight loss versus 13.7 percent with semaglutide 1.7mg or 2.4mg at 72 weeks. Wegovy 7.2mg was not tested in that trial, so there is not yet a direct head-to-head comparison of Mounjaro with the 7.2mg Wegovy dose. Our Mounjaro UK Guide covers this in full.
About this page
Page reviewed 16 September 2026. Sources checked include current MHRA Wegovy approvals and safety updates, UK product information, NICE TA875 and TA1152, STEP 1 and its withdrawal extension, STEP UP and SURMOUNT-5. This guide is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping or changing treatment.
Price comparison
Wegovy UK Price Comparison
Every UK clinic checked, so you can compare Wegovy prices before you sign up.
Key facts at a glance
Keep reading